This technology utilizes methods and compositions related to reducing the risk of or preventing fetal wastage by administering CXCR3 inhibitors.
IRAK1 is a drugable target for treatment of MDS, and IRAK1/BCL2 inhibitors synergistically co-treat MDS.
Partner with Us
View our innovation portfolio
Meet with our Team
BIO International | June 4-7
Seminar with Industry:
Mike Myers, Senior Director Lilly Research Labs